Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506705 | 0.88 | PAOX (0.38) | ACACBALDH1A1MTNR1AMTNR1BTRPV1 | |
| SCHEMBL13645921 | 0.83 | ACACB (0.36) | ACACBALDH1A1MTNR1AMTNR1BTRPV1 | |
| SCHEMBL13780937 | 0.83 | ACACB (0.36) | ACACBALDH1A1MTNR1AMTNR1BTRPV1 | |
| SCHEMBL8974574 | 0.82 | TGFBR1 (0.43) | ALDH1A1TSHR | |
| SCHEMBL24369834 | 0.79 | CYP2C9 (0.41) | ACACBALDH1A1 | |
| SCHEMBL361526 | 0.79 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL19861605 | 0.79 | TRPV1 (0.41) | ALDH1A1TRPV1TSHR | |
| Propane SCHEMBL28191962 | 0.79 | TGFBR1 (0.41) | — | |
| SCHEMBL24459288 | 0.77 | ACACB (0.39) | ACACBALDH1A1MTNR1AMTNR1B | |
| SCHEMBL13136108 | 0.77 | ACACB (0.39) | ACACBALDH1A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | disclosed |
| CN-105263906-B | The inhibitor of histone demethylase | 吉利德科学公司 | 2018-11-23 | — | — | CN | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | ACACB 444/4885ALDH1A1 168/4885MTNR1A 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.